Back to News

BioLabs Invited to Apply for Prestigious NASA Accelerator

24 September 2026Dr Paul Hilton

BioLabs has been invited to submit a proposal for the Lunar Enabling Infrastructure Accelerator (LEIA) Programme, a significant step towards pioneering deep-space biomanufacturing.

BioLabs Poised for Space-Based Innovation

BioLabs, a leading UK research-peptide and vertical-farming company, has received an exciting invitation to submit a proposal for the Lunar Enabling Infrastructure Accelerator (LEIA) Programme. This invitation marks a significant milestone for the company, potentially paving the way for BioLabs to contribute to the development of essential infrastructure for long-term human presence on the Moon.

What is the LEIA Programme?

The LEIA Programme is a forward-thinking initiative designed to accelerate the development of critical technologies and infrastructure needed for sustainable human settlements beyond Earth. It aims to identify and support innovative solutions that can enable ambitious lunar missions and the establishment of a permanent presence on the Moon. Essentially, LEIA is looking for the foundational elements that will make living and working on the Moon a reality.

BioLabs' Vision for Space Biomanufacturing

BioLabs is known for its expertise in peptide research and advanced vertical farming. The company is exploring how these capabilities can be translated into autonomous, deep-space biomanufacturing systems. Imagine a farm in space, but instead of just growing plants, it's also producing essential materials and compounds. This is the core of BioLabs' vision.

Their proposed architecture focuses on creating self-sustaining ecosystems that can operate in the challenging environment of space. This involves

  • Autonomous Operation: Systems designed to function with minimal human intervention, crucial for long-duration missions.
  • Resource Utilisation: Making the most of local lunar resources, reducing the need to transport materials from Earth.
  • Life Support: Developing closed-loop systems that can provide air, water, and food for astronauts.
  • Biomanufacturing: Producing vital substances, such as pharmaceuticals and specialised materials, directly on the Moon.

Why is this Important for Space Exploration?

Establishing a sustainable human presence on the Moon requires a robust infrastructure. This includes everything from power generation and habitat construction to food production and medical supplies. BioLabs' focus on biomanufacturing addresses a critical need: the ability to produce necessary items locally, rather than relying on costly and complex supply chains from Earth. This is akin to having a local workshop and pharmacy on the Moon.

By developing technologies that can create peptides, medicines, and potentially even food in situ, BioLabs aims to significantly reduce the logistical burden and cost of lunar missions. This will not only support astronauts but also open up new possibilities for scientific research and resource utilisation on the lunar surface.

Next Steps for BioLabs

The invitation to apply for the LEIA Programme is a testament to BioLabs' innovative approach and the potential impact of their work. The company will now focus on preparing a detailed proposal that outlines their technological capabilities, operational plans, and the specific benefits their biomanufacturing solutions can bring to lunar exploration. Success in this programme could see BioLabs playing a vital role in shaping the future of humanity's presence in space.

Attachments

Partners & Associates

UK Urban Agritech
East Suffolk Council
Growspec Global
NutraGenesis
OREX
Synergy Sphere
UK Urban Agritech
East Suffolk Council
Growspec Global
NutraGenesis
OREX
Synergy Sphere
BioLabs

The Operating System for Biologicals

EIS Round 3 Open

Navigation

Registered Office

Oxford Science Park
Oxford, OX4 4GA, UK
Co. Reg.: 15812659

Sales & Distribution

Unit 16,
Nexus Power Park
Lowestoft, NR32 1XA

In Silico Lab

Stirling University
Innovation Park
Stirling, FK9 4NF
"BioLabs™" is a Trading Style of Frontier Biolabs Ltd and Biolabs Corp Ltd

Regulatory Status

Biolabs Corp Ltd is authorised and regulated by the Financial Conduct Authority (Firm Reference Number: 1051225).

Regulatory Disclaimer

Biolabs Corp Ltd is listed on the FCA Financial Services Register under FRN 1051225. Check our registration details on register.fca.org.uk . Investment in early-stage ventures involves significant risk, including illiquidity, lack of dividends, loss of capital, and dilution.

© 2026 BioLabs. All rights reserved.